PMID: 2117046Sep 1, 1990Paper

Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals

Journal of Neurochemistry
E CarboniG Di Chiara

Abstract

The effect of systemic administration of desmethylimipramine (DMI) and oxaproptiline (OXA), two inhibitors of the noradrenaline (NA) reuptake carrier, on the in vivo extracellular concentrations of dopamine (DA) was studied by transcerebral dialysis in the prefrontal cortex and in the dorsal caudate of freely moving rats. In the NA-rich prefrontal cortex, either drug increased extracellular DA concentrations whereas in the dorsal caudate neither was effective. Haloperidol increased extracellular DA concentrations more effectively in the dorsal caudate than in the prefrontal cortex. Pre-treatment with DMI or OXA, which failed to modify the effect of haloperidol in the dorsal caudate, potentiated its action in the prefrontal cortex. 6-Hydroxydopamine lesioning of the dorsal NA bundle prevented the ability of OXA to increase DA concentrations. The results suggest that reuptake into NA terminals in an important mechanism by which DA is cleared from the extracellular space in a NA-rich area such as the prefrontal cortex. The elevated extracellular concentrations of DA resulting from blockade of such mechanism by tricyclic antidepressants may play a role in the therapeutic effects of these drugs.

References

Jan 13, 1978·Brain Research·P Levitt, R Y Moore
Mar 1, 1990·Trends in Pharmacological Sciences·G Di Chiara
Aug 22, 1989·European Journal of Pharmacology·G M De MontisA Tagliamonte
Dec 6, 1974·Brain Research·O LindvallU Stenevi
Nov 2, 1973·Science·A M ThierryJ Glowinski
Aug 1, 1965·British Journal of Pharmacology and Chemotherapy·A S Burgen, L L Iversen

❮ Previous
Next ❯

Citations

Jun 22, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Michael J Minzenberg
Jun 3, 1996·European Journal of Pharmacology·K WedzonyK Gołembiowska
Nov 13, 2003·European Journal of Pharmacology·Beatriz A Rocha
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·José A Apud, Daniel R Weinberger
Jan 31, 2004·Pharmacology, Biochemistry, and Behavior·Andreas LengBoris Ferger
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Torgny H Svensson
Jan 29, 1997·European Journal of Pharmacology·A Newman-TancrediM J Millan
Nov 5, 1999·Pharmacology, Biochemistry, and Behavior·A BessonJ Fialip
Dec 22, 1999·Pharmacology & Therapeutics·G EmilienS Cragg
Sep 2, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·E C PetrieP Szot
Dec 15, 2000·Progress in Neurobiology·T M Tzschentke
Dec 15, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roxann C HarveyKathleen M Kantak
May 14, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Monica M MarcusTorgny H Svensson
Jul 12, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yosefu ArimeIchiro Sora
Jan 11, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brooke E Schmeichel, Craig W Berridge
Jun 3, 2011·Nature Reviews. Neuroscience·Roy A Wise, Eugene A Kiyatkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here